Skip to main content
DuChemBio Co, LTD logo

DuChemBio Co, LTD — Investor Relations & Filings

Ticker · 176750 ISIN · KR7176750008 KO Manufacturing
Filings indexed 291 across all filing types
Latest filing 2024-08-19 M&A Activity
Country KR South Korea
Listing KO 176750

About DuChemBio Co, LTD

http://www.duchembio.com/en/

DuChemBio Co., Ltd. is a pharmaceutical company specializing in the development, manufacturing, and commercialization of radiopharmaceuticals. The company focuses on products for both diagnosis and treatment, with a primary emphasis on positron emission tomography (PET) imaging tracers. Its portfolio targets key therapeutic areas, including oncology for cancer detection and neurology for conditions such as Alzheimer's and Parkinson's disease. The company's mission is to develop novel radiopharmaceuticals and achieve successful commercialization on a global scale.

Recent filings

Filing Released Lang Actions
[기재정정]타법인주식및출자증권취득결정
M&A Activity Classification · 100% confidence The document is a regulatory filing from a Korean company (DuchemBio) regarding the acquisition of shares in another company (Radio DNS Labs). It details the terms of the acquisition, including the purchase price, payment method, and the rationale for the investment. This type of disclosure is a standard corporate announcement regarding M&A activity or strategic investment. Since it does not fit into specific categories like '10-K' or 'ER', and is a formal regulatory disclosure of a transaction, it is classified as a Regulatory Filing (RNS).
2024-08-19 Korean
주요사항보고서(자기주식처분결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Services Commission (금융위원회) in South Korea. It specifically details a 'Decision to Dispose of Treasury Shares' (자기주식 처분 결정). According to the provided filing definitions, the category 'Transaction in Own Shares' (POS) is the correct classification for reports regarding a company buying back or selling its own shares.
2024-08-16 Korean
타법인주식및출자증권취득결정
M&A Activity Classification · 100% confidence The document is a formal regulatory disclosure from DuChemBio regarding the acquisition of shares in another company (Radio DNS Labs). It details the acquisition price, the number of shares, the purpose of the acquisition, and the board's resolution. This type of filing, which details corporate investment and M&A-related activity, is classified as M&A Activity (TAR) within the provided schema.
2024-08-16 Korean
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '임시주주총회 결과' (Extraordinary General Meeting Results) and details the outcome of a shareholder vote, specifically the approval of an auditor appointment. This falls directly under the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2024-06-27 Korean
기업설명회(IR)개최결과
Regulatory Filings Classification · 100% confidence The document is a formal notification of the results of an Investor Relations (IR) meeting held by DuChemBio. It details the date, location, attendees, and agenda of the meeting. Since it is a regulatory announcement regarding the occurrence and outcome of an IR event rather than the presentation slides themselves, it falls under the category of general regulatory filings or announcements.
2024-06-24 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details the change in share ownership by an executive (Kim Jong Woo) of DuchemBio. This type of filing is specifically categorized as a 'Director's Dealing' (DIRS) as it reports insider transactions and changes in ownership status by company leadership.
2024-06-17 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.